How many insider trades does FilingIQ track for SUPN?

FilingIQ tracks 753 Form 4 insider transactions for SUPN (SUPERNUS PHARMACEUTICALS, INC.), covering filings from Dec 16, 2014 onwards. 141 of those were filed in the last 90 days.

Are SUPN insiders net buyers or net sellers?

Across the full Form 4 history for SUPN, 1 transactions (0%) were open-market purchases and 187 (25%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does SUPN insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is SUPN in?

SUPERNUS PHARMACEUTICALS, INC. (SUPN) is classified in the Healthcare sector, specifically Drug Manufacturers - Specialty & Generic, with a current market capitalisation of $2.94B.

SUPN insider trading

NasdaqGM Healthcare

SUPERNUS PHARMACEUTICALS, INC. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

753

Last 90 days

141

Buys / sells

0% / 25%

Market cap

$2.94B

About SUPERNUS PHARMACEUTICALS, INC.

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes products for the treatment of central nervous system (CNS) diseases in the United States. The company offers Qelbree, a non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD); GOCOVRI for the treatment of dyskinesia and levodopa/carbidopa in patients with Parkinson's Disease (PD); Oxtellar XR, an extended-release oxcarbazepine product indicated for the monotherapy treatment of partial onset epilepsy seizures; and APOKYN for the acute and intermittent treatment of hypomobility or off episodes in patients with advanced PD. It also provides Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; XADAGO for the treatment of levodopa/carbidopa in patients with PD experiencing off episodes; and MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and chronic sialorrhea. In addition, the company develops ONAPGO, which received FDA approval, for the treatment of motor fluctuations in adults with advanced PD; SPN-817, a first-in-class selective acetylcholinesterase inhibitor, which is in Phase 2 clinical trial, for the treatment of epilepsy, partial seizures, Dravet syndrome, and Lennox-Gaustaut syndrome; SPN-820, a small molecule in Phase 2 clinical trial for treating resistant depression; SPN-443, a stimulant in Phase 1 trial for the treatment of ADHD/CNS; and SPN-446, a preclinical product for CNS. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. It has a development agreement with Navitor Inc. for the conduct of Phase 2 clinical program of SPN-820. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is based in Rockville, Maryland.

Company website: www.supernus.com

SUPN insider activity at a glance

FilingIQ has scored 753 insider transactions for SUPN since Dec 16, 2014. The most recent filing in our index is dated Mar 18, 2026.

Across the full history, 1 open-market purchases and 187 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on SUPN insider trades is 63.0/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live SUPN trades on FilingIQ Raw filings on SEC EDGAR

Latest SUPN Form 4 filings

Khattar Jack A. President, CEO

S Nov 8, 2024

Khattar Jack A. President, CEO

S Nov 7, 2024

Mottola Frank SVP, Quality, GMP, Ops, IT

S Nov 7, 2024

Most recent disclosures. Sign up to filter by score, transaction code, or insider role.

Other Healthcare tickers with recent insider activity

UTHR 1,098

UNITED THERAPEUTICS Corp

APLS 279

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

BMY 185

BRISTOL MYERS SQUIBB CO

ADPT 184

Adaptive Biotechnologies Corp

GH 169

Guardant Health, Inc.

ISRG 166

INTUITIVE SURGICAL INC

VTRS 165

Viatris Inc

13F funds holding SUPN

Radcliffe Capital Management, L.P.

$67.80M · 2.2% of AUM

Frequently asked

How many insider trades does FilingIQ track for SUPN?: FilingIQ tracks 753 Form 4 insider transactions for SUPN (SUPERNUS PHARMACEUTICALS, INC.), covering filings from Dec 16, 2014 onwards. 141 of those were filed in the last 90 days.
Are SUPN insiders net buyers or net sellers?: Across the full Form 4 history for SUPN, 1 transactions (0%) were open-market purchases and 187 (25%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does SUPN insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is SUPN in?: SUPERNUS PHARMACEUTICALS, INC. (SUPN) is classified in the Healthcare sector, specifically Drug Manufacturers - Specialty & Generic, with a current market capitalisation of $2.94B.

Methodology & sources

Every SUPN insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.